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Email: j.c.verster@uu.nlLinden‐Carmichael et al. (this issue) rightly caution against prema-
turely drawing conclusions regarding the safety of consuming alcohol
mixed with energy drinks (AMED). Our aim in conducting a meta‐
analysis (Verster et al., 2018) was not to play down the risks
associated with AMED consumption, rather it was to give an objec-
tive picture of the literature on functional consequences of AMED
consumption using data available at the time of conducting the
review. Linden‐Carmichael et al. suggest that their recent diary
method paper (Linden‐Carmichael & Lau‐Barraco, 2017) casts doubt
on the conclusions of our meta‐analysis. As the paper in question
was, in the authors' words, “published after Verster and colleagues
completed their literature review,” it was not included. Nevertheless,
the paper is a welcome contribution to the AMED literature. To suggest,
however, that this single paper supersedes all previous work in the field
does seem rather premature.
Consuming alcohol in any form, including AMED, carries risks. It is
important, however, that the functional consequences of AMED and
alcohol only (AO) consumption are reported on the basis of empirical,
evidence‐based analyses. Our meta‐analysis paper confirms that,
compared with AO consumers, AMED users consume more alcohol
and are subject to more alcohol‐related harms. It is also true that
AMED consumers differ significantly from non‐AMED consumers on
a number of other dimensions, e.g., they are significantly more likely
to be male, taller, and use drugs (e.g., De Haan et al., 2012). We have
therefore cautiously suggested that AMED consumption may be, at- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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https://doi.org/10.1002/hup.2663least partly, one of several phenotypical manifestations of some other
dispositional factor or trait. One of the advantages of meta‐analysis is
that the method captures and synthesizes the extant literature. In this
case, as a secondary aim, we can examine whether the results of the
meta‐analysis are consistent with our hypothesis by focusing on any
differences in between‐subjects and within‐subjects comparisons.
AMED consumers tend to mix alcohol with energy drinks on a
minority of drinking occasions (Verster et al., 2018; Verster, Aufricht,
& Alford, 2012). If AMED consumption is one of several manifestations
of some underlying trait, we would predict that AMED consumers
would drink a similar amount of alcohol (and have a similar frequency
of alcohol‐related consequences) when they drink AMED to when they
consume AO. Alternatively, If AMED consumption is causal in produc-
ing alcohol‐related harms, then one would predict that AMED users
would drink more (and be subject to more negative alcohol‐related
consequences) on AMED occasions than on AO occasions. Our meta‐
analysis (Verster et al., 2018) shows unequivocally that (a) compared
with those who never consume AMED but consume AO, AMED
consumers drink more alcohol and, by extension, engage in more
alcohol‐related harmful behaviors (between‐subjects analysis of
N = 6,061 AMED and N = 14,496 AO consumers in total); (b) compared
with when they consume AO, on the occasions where AMED drinkers
co‐consume alcohol and energy drinks, they do not consume more alco-
hol and, by the same argument, not engage inmore alcohol‐related harm-
ful behaviors (within‐subjects analysis of N = 3,480 AMED consumers).- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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meta‐analysis, supports the notion that AMED consumption may be,
at least in part, one manifestation of an underlying trait. This is impor-
tant because better understanding of the reasons why certain individ-
uals become AMED consumers (possibly as one of a cluster of harmful
drug and alcohol related behaviors) may help in the early identification
of these individuals in order to instigate preventative measures. An
alternative view is that AMED consumption is causal in producing
alcohol‐related harms, so a better strategy would be to differentially
restrict access to AMED over other forms of alcohol. The meta‐analy-
sis supports the former. This does not preclude the possibility of other
processes, not examined in the meta‐analysis, being differentially
associated with AMED; nor does it mean there should be no further
investigation into the possible harms associated with AMED. Indeed,
as we state in the abstract of our paper, “Further research may be nec-
essary to fully reveal the effects of AMED.” (Verster et al., 2018).
Linden‐Carmichael et al. (this issue) identify possible problems with
survey methods, in particular that they can be subject to recall bias—pre-
sumably with this recall bias differentially affecting memory of AMED
over AO occasions. Specifically, this would require recall bias to result
in under‐reporting of harms during AMED but not AO occasions. No
mechanism is put forward for this differential effect, although it may be
that, as AMED consumers tend to drink AO on the majority of occasions,
there is more opportunity to recall AO‐related harms. It is certainly true
that such studies are imperfect, but they can provide useful information
for meta‐analyses and reviews. For example, the same authors' 2014
“qualitative review of psychosocial risk factors” associated with AMED
use concludes that “use of such beverages is associated with negative
consequences including heavy alcohol use, risky sexual and driving
behaviors, as well as other drug use” (Linden & Lau‐Barraco, 2014). Nota-
bly, when rallying around 20 surveys to support their contention, the
authors did not once mention the possibility of recall bias.
We concur with Linden‐Carmichael et al. (this issue) that AMED
research presents its own unique problems. Unfortunately, this
research area has been undermined to some degree by selective
reporting of the harms associated with AMED. However, we believe
that meta‐analyses can provide useful information that may be
complemented and challenged by single studies but not undermined
by them. As an example, Linden‐Carmichael and Lau‐Barraco (2017)
suggest that “one reason for the link between CAB use and alcohol
outcomes may be that caffeine can reduce one's feelings of intoxica-
tion without reducing actual drunkenness” (note that CAB refers to
caffeinated alcoholic beverage, including AMED). The phenomenon
of “masking”, the notion that coconsuming caffeine with alcohol could
reduce perceived intoxication while leaving alcohol impairment
unaffected is not supported by the literature. Rather than reference
a meta‐analysis (Benson, Verster, Alford, & Scholey, 2014), which
included all subjective intoxication studies, Linden‐Carmichael and
Lau‐Barraco (2017) cite a single study by Marczinski and Fillmore
(2006) to support this contention. They report that Marczinski and
Fillmore “found after consuming CABs as opposed to regular alcohol,
participants felt less intoxicated” (p. 882). In fact, despite an abstract
concluding that “subjective measures of intoxication showed that
coadministration of caffeine with alcohol reduced participants'
perceptions of alcohol intoxication compared with administration ofalcohol alone” (Marczinski & Fillmore, 2006), this finding is not as
clear as stated. The study reported that a lower (2 mg/kg) dose,
equivalent to an average of around 140 mg of caffeine in their sam-
ple, reduced self‐rated alcohol intoxication, whereas a higher (4 mg/
kg or 280 mg) dose of caffeine did not. Further, Marczinski and Fill-
more state that “coadministration of 2.0 mg/kg of caffeine with alco-
hol significantly lowered beverage ratings [a measure of subjective
intoxication] as compared with alcohol alone, t(11) = 1.77, p = .05”
(p. 455). Taken at face value, a lower but not a higher dose of caffeine
had, at most, a marginally significant effect on perceived intoxication.
The picture is further complicated, however, by a statistical anomaly in
the Marczinski and Fillmore (2006) paper, which has previously been
alluded to (Benson et al., 2014; Benson & Scholey, 2014). Their reported
t value of 1.77 with 11 degrees of freedom is associated with a p value of
.052 (one tailed) or .14 (two tailed), so strictly speaking was not signifi-
cant. It is unclear why Linden‐Carmichael and Lau‐Barraco (2017) would
choose to cite the results of one of two arms in a single study over a well‐
conductedmeta‐analysis (or indeed several papers byMarczinski's group,
which did not find a masking effect). It does, however, illustrate the pit-
falls of choosing a single study (or in this case, one dose from a single
study) over a more thorough synthesis of the data. The nature of meta‐
analyses enables more representative findings to emerge and to indicate
which individual studies are outliers.
Unfortunately, this is not simply an academic exercise. Expectan-
cies about the effects of drugs can affect their outcomes. In an elegant
experiment, Fillmore, Roach, and Rice (2002) showed that when sub-
jects were led to expect that caffeine reversed the effects of alcohol,
the consequence was increased impairment when alcohol was mixed
with caffeine. Thus, falsely suggesting that masking occurs, or that
AMED harms exist if they do not, could have serious real‐world conse-
quences if they are publicized and believed by AMED users.
There is a dearth of prospective cohort studies comparing AMED
and AO effects, and many of the studies in this field have methodological
flaws. Thus, Linden‐Carmichael et al. (this issue) rightly indicate that their
recent diary paper has certain advantages. For example, their approach
allowed drinking patterns and functional consequences to be captured
the next day rather than weeks or months later. This does not mean,
however, that the paper is the last word on AMED‐related harms. There
are also a number of issues regarding data analysis and reporting.
Linden‐Carmichael and Lau‐Barraco (2017) selected N = 122
AMED consumers, described as “heavy drinking, college student
CAB users” (note that CAB = caffeinated alcoholic beverage, so
includes AMED as well as alcohol with other mixers, specifically “Diet
and regular soda.”) Each completed an average of 12.42 entries,
allowing, during the 2‐week period, 1,515 opportunities to consume
alcohol for the whole sample, of which 389 (25.67%) were taken.
The majority (74.04%) of these drinking occasions involved non‐CAB
rather than CAB drinks (presented as 288 vs. 101 in Table 1 of the
paper). Most of the 101 CAB occasions involved non‐AMED
beverages (71 vs. 40 in Table 1). Although, given that 71 + 40 = 111,
there may have been 10 occasions when CAB drinker consumed both.
Confusingly, the paper states that of “CAB days, cola‐caffeinated
alcoholic beverages were consumed on 57.43% of CAB days and
alcohol mixed with energy drinks [AMED] were consumed on 39.6%
of CAB days.” While the figure for AMED is consistent with Table 1,
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57.43% of 101 is 58, whereas Table 1 reports that soda and alcohol
drinks were consumed on 71 out of 101 (70.3%) of CAB occasions.
The reason for this anomaly is unclear; it may be that the authors have
differentiated noncaffeinated soda from caffeinated mixers although
elsewhere the paper states that both diet and regular soda were
considered “cola‐caffeinated mixers” (p. 884).
Forty AMED occasions were recorded over 14 days in 122 AMED
consumers. In other words, the majority of this cohort of “heavy
drinking, college student CAB users” did not consume CAB or AMED
over the 14‐day study period. Taking number of diary completions
into account, they consumed AMED on 2.64% of days available to
them (extrapolating these data would translate to nine or 10 AMED
occasions in a year).
Unfortunately, the paper does not specify how many individuals
contributed to the 40 AMED occasions, which could range from four
individuals each consuming AMED on 10 occasions to 40 individuals
each consuming AMED once. We did request this information from
the authors, but, at the time of writing this response no data were
received. Linden‐Carmichael and Lau‐Barraco (2017) concluded that
there were more alcohol‐related harms following AMED than AO. Lin-
den‐Carmichael (this issue) suggest that their study is superior due to
their within‐subjects analysis, stating that the “study compared days in
which individuals consumed CABs as opposed to days in which they
consumed other types of alcohol.” Strictly speaking this is not
accurate. It would be more correct to state that the study compared
CAB with non‐CAB occasions within a cohort of CAB users. A more
appropriate approach would be to conduct a true within‐subjects
comparison among only those subjects who experienced both AMED
and AO occasions within the 14‐day period. This may be possible
because the paper states that there were 50.80% (N = 62) individuals
who consumed both non‐CAB and CAB (although the number of
AMED users within this subset is not specified). Comparing functional
consequences of AMED within the same drinkers (a true within‐sub-
ject comparison) over the period of study would have provided useful
information regarding the role of AMED in alcohol harms.
Findings from the Linden‐Carmichael and Lau‐Barraco (2017) study
need to be replicated (perhaps addressing some of the shortcomings
outlined above). They do not change the validity of our meta‐analysis
and its outcome that “mixing alcohol with energy drink does not affect
subjective intoxication and seems unlikely to increase total alcohol
consumption, associated risk‐taking behavior, nor other negative alcohol
related consequence.” Taken together, we are pleased to have this
opportunity to respond to Linden‐Carmichael et al. (this issue) and
believe that, as concluded in Verster et al. (2018), “Further research
may be necessary to fully reveal the effects of AMED.”CONFLICT OF INTEREST
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